Tibotec, a division of Janssen-Ortho Inc., announced today that Health Canada has approved PREZISTA* (darunavir) for use in treatment-naive adults (those who have never taken HIV medication before), dosed once daily in combination with other antiretroviral agents. The new indication for PREZISTA includes a new tablet strength of 400 mg to support the recommended dosing regimen.
the details can be read here.
No comments:
Post a Comment